title: Human pharmacology of renzapride: a new gastrokinetic benzamide without dopamine antagonist properties.
abstract: The activity of the substituted benzamide renzapride on the upper gastrointestinal tract has been investigated. It has been shown to enhance stomach emptying in normal subjects; doses of 2 and 5 mg decreasing by 21 and 37% respectively the volume of gastric contents aspirated 80 min after a test meal. Renzapride was found to reduce the oro-caecal transit time as assessed by the lactulose/breath hydrogen method in a dose related manner from 0.2 to 5 mg; the later dose producing a 62% reduction. Finally renzapride was shown not to elevate plasma prolactin at a dose of 5 mg, a finding consistent with lack of dopamine receptor antagonism.
authors.affiliation: Beecham Clinical Pharmacology Unit, West Middlesex University Hospital, Isleworth.
authors.forename: D H
authors.initials: DH
authors.lastname: Staniforth
authors.forename: M
authors.initials: M
authors.lastname: Pennick
mesh_terms: D000328:Adult; D001549:Benzamides / Q000493:pharmacokinetics / Q000494:pharmacology*; D001944:Breath Tests; D001643:Bridged Bicyclo Compounds / Q000493:pharmacokinetics / Q000494:pharmacology*; D019086:Bridged Bicyclo Compounds, Heterocyclic; D001952:Bridged-Ring Compounds / Q000494:pharmacology*; D005746:Gastric Emptying / Q000187:drug effects*; D005772:Gastrointestinal Transit / Q000187:drug effects; D006801:Humans; D007792:Lactulose; D008297:Male; D008787:Metoclopramide / Q000494:pharmacology; D011388:Prolactin / Q000097:blood; D011897:Random Allocation
chemical_list: D001549:Benzamides; D001643:Bridged Bicyclo Compounds; D019086:Bridged Bicyclo Compounds, Heterocyclic; D001952:Bridged-Ring Compounds; D007792:Lactulose; D011388:Prolactin; C053006:renzapride; D008787:Metoclopramide